The second patient was a 28-year-old female with PIK3CA-mutated metastatic embryonal rhabdomyosarcoma, who was treated with everolimus after progression on vincristine, dactinomycin, and cyclophosphamide. This evidence concerns the gene PIK3CA and embryonal rhabdomyosarcoma.